Tumors, an mRNA vaccine against melanoma could be ready in three years. This was confirmed to beraking latest news Salute by Giuseppe Curigliano, professor of medical oncology at the University of Milan, on the sidelines of the presentation of the 4th Italian Summit On Precision Medicine, an event that opens today in Rome organized by the Foundation for Personalized Medicine (Fmp). «I am convinced that the mRNA vaccine against melanoma will certainly reach registration. The times will not be long, there is a registration study underway, but it will take at least 3 years”, said Curigliano
INSIGHTS
«This technology will also have an impact on two other pathologies, lung tumors and triple negative breast cancers, on which there will soon be studies», continues Curigliano, recalling that we have seen the benefits of this very innovative methodology «developed for vaccines, against Covid . And in some oncological diseases it will certainly make a strong contribution.”
He is vaccinated 217 times against Covid. “No side effects.” The (incredible) story of a 62 year old German
How does it work
These are products that «use synthetic mRNAs designed to “instruct” the immune system to recognize specific proteins, called ‘neoantigens, which are the expression of genetic mutations that have occurred in diseased cells», explains Paolo Ascierto, president of the conference and director of the Department of melanoma oncology, oncological immunotherapy and innovative Pascale therapies.
Mortality
The purpose of the vaccine “is not to prevent the disease – he specifies – but to help and support the patients’ immune system to recognize and attack the tumor more effectively”. The data 2 years after the administration of the mRNA vaccine against melanoma – recalls a note – show a reduction in the risk of recurrence or death of 44% in those who received it in combination with the immunotherapy drug pembrolizumab. «It will take a few years before we have the results of this last clinical phase – Ascierto points out – Our hope is to be able to give a new and more effective therapeutic option to as many patients as possible».
© ALL RIGHTS RESERVED